Appeals court rules in favor of Watson in Sanctura XR patent suit

PARSIPPANY, N.J. — The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker's abbreviated new drug application for an overactive bladder treatment.

The appeals court affirmed a U.S. District Court for the District of Delaware's decision — made March 31 — that asserted that patents related to Allergan's Sanctura XR (trospium chloride extended-release capsules) are invalid. Watson's ANDA for a generic version of Sanctura XR is pending with the Food and Drug Administration.

Sanctura XR had total U.S. sales of approximately $66 million for the 12 months ended in April, according to IMS Health data.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.